- PR Newswire•2 days agoNovartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
EAST HANOVER, N.J., Sept. 23, 2016 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of Ilaris ® (canakinumab) ...
- Zacks•2 days ago
Novartis (NVS) announced positive top-line data from the phase III ASCEND-4 study on Zykadia to treat patients with ALK+ NSCLC.
- Reuters•2 days ago
Novartis's Zykadia drug performed well against a rare form of lung cancer, the Swiss company said on Friday, citing a study it hopes will help it win expanded regulatory approval for the use of the drug. Novartis released results of a phase III clinical trial of Zykadia, or ceritinib, on previously untreated patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. Patients treated with Zykadia showed a significant improvement in their chances of surviving without the cancer spreading compared with standard chemotherapy, the firm said.
Novartis AG (NVS)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||78.08 x 100|
|Ask||83.15 x 100|
|Day's Range||81.09 - 81.68|
|52wk Range||69.90 - 95.11|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||29.09|
|Avg Vol (3m)||1,331,220|
|Dividend & Yield||2.72 (3.34%)|